881 related articles for article (PubMed ID: 19272537)
1. Neuromuscular transmission: new concepts and agents.
de Boer HD
J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacology of sugammadex.
Bom A; Hope F; Rutherford S; Thomson K
J Crit Care; 2009 Mar; 24(1):29-35. PubMed ID: 19272536
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of new neuromuscular concepts and agents: so long, neostigmine! So long, sux!
Lee C; Katz RL
J Crit Care; 2009 Mar; 24(1):43-9. PubMed ID: 19272538
[TBL] [Abstract][Full Text] [Related]
4. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
[TBL] [Abstract][Full Text] [Related]
5. Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.
Ren WH; Jahr JS
Am J Ther; 2009; 16(4):295-9. PubMed ID: 19535969
[TBL] [Abstract][Full Text] [Related]
6. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
Khuenl-Brady KS; Wattwil M; Vanacker BF; Lora-Tamayo JI; Rietbergen H; Alvarez-Gómez JA
Anesth Analg; 2010 Jan; 110(1):64-73. PubMed ID: 19713265
[TBL] [Abstract][Full Text] [Related]
7. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
Abrishami A; Ho J; Wong J; Yin L; Chung F
Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
[TBL] [Abstract][Full Text] [Related]
8. A novel approach to reversal of neuromuscular blockade.
Della Rocca G; Pompei L
Minerva Anestesiol; 2009 May; 75(5):349-51. PubMed ID: 19412157
[TBL] [Abstract][Full Text] [Related]
9. Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy.
de Boer HD; van Esmond J; Booij LH; Driessen JJ
Paediatr Anaesth; 2009 Dec; 19(12):1226-8. PubMed ID: 19863737
[TBL] [Abstract][Full Text] [Related]
10. Sugammadex: the first selective binding reversal agent for neuromuscular block.
Kovac AL
J Clin Anesth; 2009 Sep; 21(6):444-53. PubMed ID: 19833281
[TBL] [Abstract][Full Text] [Related]
11. Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.
Hogg RM; Mirakhur RK
Expert Rev Neurother; 2009 May; 9(5):599-608. PubMed ID: 19402771
[TBL] [Abstract][Full Text] [Related]
12. Sugammadex in clinical practice.
Mirakhur RK
Anaesthesia; 2009 Mar; 64 Suppl 1():45-54. PubMed ID: 19222431
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of sugammadex.
Caldwell JE; Miller RD
Anaesthesia; 2009 Mar; 64 Suppl 1():66-72. PubMed ID: 19222433
[TBL] [Abstract][Full Text] [Related]
14. Sugammadex: another milestone in clinical neuromuscular pharmacology.
Naguib M
Anesth Analg; 2007 Mar; 104(3):575-81. PubMed ID: 17312211
[TBL] [Abstract][Full Text] [Related]
15. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
Duvaldestin P; Kuizenga K; Saldien V; Claudius C; Servin F; Klein J; Debaene B; Heeringa M
Anesth Analg; 2010 Jan; 110(1):74-82. PubMed ID: 19933538
[TBL] [Abstract][Full Text] [Related]
16. Sugammadex: a selective relaxant-binding agent providing rapid reversal.
Rex C; Bergner UA; Pühringer FK
Curr Opin Anaesthesiol; 2010 Aug; 23(4):461-5. PubMed ID: 20489603
[TBL] [Abstract][Full Text] [Related]
17. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
Sacan O; White PF; Tufanogullari B; Klein K
Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
[TBL] [Abstract][Full Text] [Related]
18. The use of sugammadex in a patient with myasthenia gravis.
Unterbuchner C; Fink H; Blobner M
Anaesthesia; 2010 Mar; 65(3):302-5. PubMed ID: 20105151
[TBL] [Abstract][Full Text] [Related]
19. Reversal of profound rocuronium or vecuronium-induced neuromuscular block with sugammadex in isoflurane-anaesthetised dogs.
Mosing M; Auer U; West E; Jones RS; Hunter JM
Vet J; 2012 Jun; 192(3):467-71. PubMed ID: 22030475
[TBL] [Abstract][Full Text] [Related]
20. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.
Pühringer FK; Rex C; Sielenkämper AW; Claudius C; Larsen PB; Prins ME; Eikermann M; Khuenl-Brady KS
Anesthesiology; 2008 Aug; 109(2):188-97. PubMed ID: 18648227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]